We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Biostructures Expands Successful Protein Crystallography Collaboration with OSI Pharmaceuticals
News

Proteros Biostructures Expands Successful Protein Crystallography Collaboration with OSI Pharmaceuticals

Proteros Biostructures Expands Successful Protein Crystallography Collaboration with OSI Pharmaceuticals
News

Proteros Biostructures Expands Successful Protein Crystallography Collaboration with OSI Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Biostructures Expands Successful Protein Crystallography Collaboration with OSI Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH (‘Proteros’) has announced the expansion of its collaboration with OSI Pharmaceuticals, Inc. (OSI) in the field of protein crystallography.

Following the successful delivery of valuable high resolution protein-ligand-structures on multiple kinase targets under Proteros’ Gallery Structure mode with compounds supplied by OSI, Proteros will now provide also Gene-to-Structure services to OSI.

This Gene-to-Structure agreement marks the fifth project under the master service agreement signed in October 2007. Under it Proteros will utilize its capabilities in construct design, protein expression and purification as well as protein structure determination to deliver a de novo protein structure and several protein-ligand-structures on a challenging kinase target to OSI.

Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “The successes so far demonstrate that the combination of Proteros’ industrial approach, unique technologies and expertise can quickly generate valuable structural data to meet the highest quality standards required by OSI. We look forward to continuing to demonstrate the value of this collaboration and contributing to accelerating drug discovery programmes at OSI.”

Advertisement